関連する実験動画
Updated: Aug 13, 2026

08:23
Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes
Published on: March 2, 2020
シプロフロキサシンの排泄は,汗と多耐性スタフィロコクス・エピダーミディスによるものです
1Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, Denmark.
Lancet (London, England)
|January 18, 1997
まとめ
汗によるシプロフロキサシンの排泄は,健康な個体でも,Staphylococcus epidermidisの耐性を急速に駆動する. この抗生物質耐性は,皮膚細菌で急速に発達し,治療が終了した後も長期間持続しました.
科学分野:
- 微生物学 微生物学とは
- 薬理学 薬理学とは
- 皮膚科 皮膚科について
背景:
- Staphylococcus epidermidisは,シプロフロクサシンに対する抵抗性の急速な発達を示しています.
- シプロフロキサチンは,人間の汗で分泌され,潜在的に抵抗性に貢献します.
- この研究では,シプロフロキサシン治療後の頭および鼻の菌群におけるS. epidermidisの耐性開発を調査した.
研究 の 目的:
- 健康な個人の帯および鼻の植物からS. epidermidisにシプロフロキサシン耐性の発生を評価する.
- 汗中のシプロフロキサシン濃度と耐性開発を相関させるため.
- 治療後の耐性菌株の持続性を判断する.
主な方法:
- 7人のボランティアは,口服によるシプロフロクサシン (750 mg,毎日2回,7日間) を受けた.
- 汗中のシプロフロキサシン濃度が測定されました.
- 治療中に,そして治療後,頭と鼻の穴におけるS. epidermidisの耐性をモニタリングした.
- S. epidermidisのゲノタイプ化は,制限断片長ポリモルフィズムを使用して行われました.
主要な成果:
- 治療中に汗中のシプロフロクサシン濃度が上昇し,5.5マイクログラム/mLに達しました.
- シプロフロキサシン耐性S.epidermidis菌株 (中級および高レベル) は,すべての参加者において検出されました.
- 耐性は,状S.epidermidis (平均2.7日) と鼻状S.epidermidis (平均11日) で急速に発達した.
- 治療後の約37~39日間,耐性菌株が持続した.
結論:
- S. epidermidisにおけるシプロフロクサシン耐性の急速な発達は,汗による薬物の排泄と関連しています.
- この現象は,臨床およびコミュニティの環境で多剤耐性細菌の出現に寄与する可能性があります.
- 高いシプロフロキサシン使用量は,皮膚の菌群における抗生物質耐性の問題を悪化させる可能性があります.
さらに関連する動画
関連する概念動画
Drug Elimination by Renal Route: Tubular Secretion
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
Drug Elimination: Non-Renal Routes
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
Surface Membrane Barriers
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
Drug Excretion: Miscellaneous Routes
Drug excretion involves various organs, including the liver, intestines, skin, and eyes. In the case of drugs or toxins, they can be actively secreted into bile by transporters in the hepatocyte's canalicular membrane. These substances enter the GI tract during digestion and may be reabsorbed into the body from the intestine. This process, known as enterohepatic recycling, can significantly prolong the presence and effects of a substance in the body. To interrupt this cycle, specific substances...
Staphylococcal Skin Infections
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...

